XML 60 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Cash flows from operating activities:    
Net income $ 142,593 $ 103,065
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 8,291 6,635
Loss on disposition of assets 52 4
Share-based compensation expense 20,503 20,435
Bad debt expense 30,968 23,103
Impairment of intangible asset   1,490
Accreted interest on note receivable (3,337) (2,000)
Unrecognized tax benefits 2,923 470
Excess tax benefit from share-based compensation (5,109) (5,265)
Deferred income taxes 1,827 5,020
Changes in operating assets and liabilities:    
Prepaid expenses (837) 178
Trade accounts receivable (17,307) (55,834)
Other receivables (587) 473
Prepaid Taxes (12,360)  
Inventory (10,395) 4,438
Accounts payable (5,635) 2,097
Accrued liabilities (2,233) 5,580
Deferred revenue (77) 977
Net cash provided by operating activities 149,280 110,866
Cash flows from investing activities:    
Capital expenditures for equipment and leasehold improvements (9,653) (8,582)
Acquisition of Crescendo Biosciences, Inc. (see Note 9), net of cash acquired (223,531)  
Purchases of marketable investment securities (105,451) (281,774)
Proceeds from maturities and sales of marketable investment securities 340,829 299,395
Net cash provided by investing activities 2,194 9,039
Cash flows from financing activities:    
Net proceeds from common stock issued under share-based compensation plans 47,156 25,506
Excess tax benefit from share-based compensation 5,109 5,265
Repurchase and retirement of common stock (222,014) (124,705)
Net cash used in financing activities (169,749) (93,934)
Net (decrease) increase in cash and cash equivalents (18,275) 25,971
Cash and cash equivalents at beginning of period 104,073 86,352
Cash and cash equivalents at end of period $ 85,798 $ 112,323